Clinical Trial Update: ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase Ib/II clinical trial, ERADICATE, is evaluating elacestrant in combination with trastuzumab deruxtecan in patients with HR-positive, endocrine-resistant,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Elacestrant (elacestrant)
• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Sarah Sammons, MD | Conditions: Metastatic Breast Cancer, HER2 Low Breast Carcinoma | Phase 1, Phase 2 | Status: RECRUITING